Appendix Table 3.
Variation in Utilities Based on EORTC QLC-30/QLC-LC13 at Baseline Survey
| Demographic | Patients with EORTC N (%) | EORTC Score* Mean (SD) | EORTC Score* Median (IQR) |
|---|---|---|---|
|
| |||
| All | 2212 (100%) | 21.94 (6.11) | 21.0 (9.0) |
|
| |||
| Sex | |||
| Male | 1171 (52.9%) | 21.79 (5.93) | 21.0 (9.0) |
| Female | 1041 (47.1%) | 22.10 (6.31) | 21.0 (9.0) |
| p-value† | 0.50 | ||
|
| |||
| Race/Ethnicity | |||
| Caucasian | 1655 (74.8%) | 21.75 (5.91) | 21.0 (8.0) |
| Latino | 92 (4.2%) | 21.16 (5.70) | 20.5 (8.0) |
| African American | 255 (11.5%) | 22.95 (6.79) | 22.0 (11.0) |
| Asian | 80 (3.6%) | 19.93 (4.88) | 20.0 (7.0) |
| Other | 130 (5.9%) | 24.07 (7.34) | 23.0 (9.0) |
| p-value‡ | 0.0001 | ||
|
| |||
| Age | |||
| <=54 | 339 (15.35) | 24.13 (7.26) | 23.0 (11.0) |
| 55-59 | 286 (12.9%) | 22.94 (5.97) | 23.0 (9.0) |
| 60-64 | 339 (15.3%) | 22.55 (6.28) | 21.0 (8.0) |
| 65-69 | 385 (17.4%) | 21.34 (5.95) | 21.0 (8.0) |
| 70-74 | 365 (16.5%) | 21.09 (5.56) | 20.0 (7.0) |
| 75-79 | 289 (13.1%) | 20.89 (5.06) | 21.0 (7.0) |
| 80+ | 209 (9.5%) | 20.07 (5.14) | 19.0 (7.0) |
| p-value‡ | <0.0001 | ||
|
| |||
| Stage at Diagnosis | |||
| I | 684 (30.9%) | 20.33 (5.64) | 19.0 (7.0) |
| II | 213 (9.6%) | 22.42 (5.79) | 22.0 (8.0) |
| III | 599 (27.1%) | 22.96 (6.28) | 22.0 (9.0) |
| IV | 587 (26.5%) | 22.58 (6.16) | 22.0 (8.0) |
| Unknown/Missing | 129 (5.8%) | 21.94 (6.39) | 21.0 (9.0) |
| p-value‡ | <0.0001 | ||
|
| |||
| Histology | |||
| NSCLC | 1869 (84.6%) | 21.74 (5.94) | 23.0 (10.0) |
| SCLC | 242 (10.9%) | 22.67 (6.87) | 21.0 (8.0) |
| Missing | 101 (4.6%) | 22.77 (6.92) | 21.5 (10.0) |
| p-value‡ | n.s. | ||
|
| |||
| Treatment | |||
| Surgery | 517 (23.4%) | 19.79 (5.50) | 19.0 (7.0) |
| Chemotherapy | 325 (14.7%) | 22.04 (6.19) | 21.0 (9.0) |
| Radiotherapy | 109 (4.9%) | 21.93 (6.10) | 21.0 (9.0) |
| Surgery w/Chemotherapy | 252 (11.4%) | 22.58 (5.76) | 22.0 (8.0) |
| Surgery w/Radiotherapy | 58 (2.6%) | 21.47 (5.69) | 21.0 (7.0) |
| Chemoradiotherapy | 639 (28.9%) | 23.21 (6.31) | 23.0 (8.0) |
| Surgery w/Chemo/Rad | 195 (8.8%) | 23.18 (6.11) | 23.0 (9.0) |
| No Treatment | 117 (5.3%) | 20.92 (5.68) | 20.0 (8.0) |
| p-value‡ | <0.0001 | ||
|
| |||
| Comorbidity | |||
| None | 388 (17.5%) | 21.67 (6.05) | 21.0 (9.0) |
| Mild | 686 (31.0%) | 21.89 (6.30) | 21.0 (8.0) |
| Moderate | 374 (16.9%) | 22.34 (6.07) | 21.0 (8.0) |
| Severe | 344 (15.6%) | 22.78 (6.18) | 22.0 (8.0) |
| Unknown/Missing | 420 (19%) | 21.21 (5.74) | 20.0 (8.0) |
| p-value‡ | 0.03 | ||
*
14 lung cancer-specific questions from EORTC QLC LC13, maximum total score is 56 (worse health).
†
Mann-Whitney U test.
‡
Kruskal-Wallis test